PMID- 25424534
OWN - NLM
STAT- MEDLINE
DCOM- 20160620
LR  - 20181202
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 33
IP  - 4
DP  - 2015 Dec
TI  - Economic evaluation of arsenic trioxide for treatment of newly diagnosed acute 
      promyelocytic leukaemia in Canada.
PG  - 229-38
LID - 10.1002/hon.2176 [doi]
AB  - To assess, from a Canadian perspective, the economic impact of arsenic trioxide 
      (ATO) + all-trans retinoic acid (ATRA) for treating newly diagnosed acute 
      promyelocytic leukaemia (APL), the cost-effectiveness of ATO + ATRA compared to 
      ATRA + idarubicin (IDA) was assessed over a lifetime horizon using a 
      time-dependent Markov model. The model considers four health states: complete 
      remission, treatment failure or relapse, post-failure, and death. Markov cycle 
      length was 1 month for the first 48 months and 1 year thereafter. Efficacy 
      outcomes in terms of event-free survival and overall survival were taken from a 
      head-to-head clinical trial. Costs were associated with drug and administration, 
      adverse events (AEs), treatment of relapses, follow-up visits, and productivity 
      losses. Utilities and disutilities associated with health states and AEs were 
      derived from the literature. Compared to ATRA + IDA, ATRA + ATO is associated 
      with incremental cost-effectiveness ratios (ICERs) of $CAD50,193/quality-adjusted 
      life years (QALY) and $CAD50,338/QALY from a Canadian Ministry of Health (MoH) 
      and societal perspectives, respectively. Results of the one-way sensitivity 
      analysis show that ICER varied from $CAD23,045 to $CAD60,759/QALY (MoH 
      perspective) and from $CAD23,120 to $CAD60,905/QALY (societal perspective). ATO 
      in the first-line therapy for patients with APL can be considered a more 
      cost-effective strategy than standard treatment from a Canadian perspective.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Lachaine, Jean
AU  - Lachaine J
AD  - Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
FAU - Mathurin, Karine
AU  - Mathurin K
AD  - Faculty of Pharmacy, University of Montreal, Montreal, QC, Canada.
FAU - Barakat, Stephane
AU  - Barakat S
AD  - Market Access and Health Outcomes, Lundbeck Canada Inc., Montreal, QC, Canada.
FAU - Schuh, Andre C
AU  - Schuh AC
AD  - Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
LA  - eng
PT  - Journal Article
DEP - 20141125
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Arsenicals)
RN  - 0 (Oxides)
RN  - S7V92P67HO (Arsenic Trioxide)
SB  - IM
MH  - Arsenic Trioxide
MH  - Arsenicals/*economics/therapeutic use
MH  - Canada
MH  - Cost-Benefit Analysis/*methods
MH  - Female
MH  - Humans
MH  - Leukemia, Promyelocytic, Acute/*drug therapy
MH  - Male
MH  - Oxides/*economics/therapeutic use
OTO - NOTNLM
OT  - Canada
OT  - acute promyelocytic leukaemia
OT  - all-trans retinoic acid
OT  - arsenic trioxide
OT  - cost-effectiveness
OT  - cost-utility
EDAT- 2014/11/27 06:00
MHDA- 2016/06/21 06:00
CRDT- 2014/11/27 06:00
PHST- 2014/09/10 00:00 [received]
PHST- 2014/09/30 00:00 [accepted]
PHST- 2014/11/27 06:00 [entrez]
PHST- 2014/11/27 06:00 [pubmed]
PHST- 2016/06/21 06:00 [medline]
AID - 10.1002/hon.2176 [doi]
PST - ppublish
SO  - Hematol Oncol. 2015 Dec;33(4):229-38. doi: 10.1002/hon.2176. Epub 2014 Nov 25.